Create Account | Sign In: Author or Forum

Search Symptoms

Category: Internal Medicine | Emergency Medicine | Nursing | Oncology | Pharmacy | Anesthesiology & Pain | Journal

Back to Journal Articles

Treatment at Infusion Center Beneficial in Sickle Cell Disease

Last Updated: July 07, 2021.

WEDNESDAY, July 7, 2021 (HealthDay News) -- For adults with sickle cell disease (SCD) with uncomplicated vaso-occlusive crises, outcomes are significantly better with treatment at an infusion center (IC) compared with an emergency department (ED), according to a study published online July 6 in the Annals of Internal Medicine.

Sophie Lanzkron, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a prospective cohort study involving adults with SCD living within 60 miles of a study site. A total of 483 participants were enrolled; 269 had acute care visits on weekdays and were included in the study.

The researchers found that the mean time to first dose of parenteral pain medication was 62 and 132 minutes in ICs and EDs, respectively. Compared with the ED, the probability of pain reassessment within 30 minutes of the first dose of parenteral pain medication was 3.8 times greater in the IC. Compared with treatment in an ED, the probability that a participant's visit would end in discharge home was 4.0 times greater with treatment in an IC.

"The value in the IC model must be recognized as important because the model offers a better way to manage this horrific disease," writes the author of an accompanying editorial. "It is equally important that the IC model is recognized as valuable to the hospital system -- or as a requirement to do what is right for those living with SCD."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Previous: Mental, Physical, Sexual Abuse Up for Transgender Adolescents Next: Mortality Rates for Those Entering HIV Care Reduced Over Time

Reader comments on this article are listed below. Review our comments policy.

Submit your opinion: